Hoag at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

Hoag takes part in 2 sessions at CTAD 2026 in Boston. Its program combines a first-in-human cell therapy with real-world blood test performance. Its work covers intracerebroventricular injection of autologous adipose-derived stem cells and commercial plasma biomarkers in an anti-amyloid treatment clinic.

Organization	CTAD 2026 Attendance
Hoag Newport Beach, California
	Poster Wed Nov 18 7:15am–5:30pm Not a Substitute for Confirmation: The Performance of Commercial Plasma Biomarkers in a Real-World Anti-Amyloid Treatment Pathway (P245) Blood and CSF biomarkers · Real-world data and access Talk Wed Nov 18 10:05am Results of a Phase 1 Trial of Intracerebroventricular Injection of Autologous, Wnt-Activated, Adipose-Derived Stem Cells for Alzheimer’s Disease; a First-in-Human Study Other mechanisms and targets

Organization

CTAD 2026 Attendance

Hoag

Newport Beach, California

Poster

Wed Nov 18
7:15am–5:30pm

Not a Substitute for Confirmation: The Performance of Commercial Plasma Biomarkers in a Real-World Anti-Amyloid Treatment Pathway (P245)

Blood and CSF biomarkers · Real-world data and access

Talk

Wed Nov 18
10:05am

Results of a Phase 1 Trial of Intracerebroventricular Injection of Autologous, Wnt-Activated, Adipose-Derived Stem Cells for Alzheimer’s Disease; a First-in-Human Study

Other mechanisms and targets

Instantly find 20 buyers from Hoag

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction